Galectin Therapeutics Inc.
GALTNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for GALT. That does not mean none is planned.
Get an email about GALT's next catalysts
Track Galectin Therapeutics (GALT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
GALT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.05 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
belapectin | Phase 3 | Prevention of Esophageal Varices | - | - |
GR-MD-02 | Phase 2 | Psoriasis | - | - |
Frequently asked questions
What is in Galectin Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Galectin Therapeutics Inc.'s (GALT) pipeline across Phase 3, Phase 2. Its lead program is belapectin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galectin Therapeutics Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Galectin Therapeutics Inc. (GALT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GALT biotech catalysts?→
Add GALT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galectin Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.